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Acute GVHD has remained a signiﬁcant cause of
nonrelapse mortality after allogeneic hematopoietic cell
transplantation (HCT) with nonmyeloablative condition-
ing. The role of TNF-a in the biology of acute GVHD
after nonmyeloablative conditioning has not been studied
thus far. Here, we measured TNF receptor 1 (TNFR1)
as a surrogate marker for TNF-a in 106 patients
before the start of the conditioning regimen (baseline)
and 7 days after allogeneic HCT with nonmyeloablative
conditioning. The nonmyeloablative regimen consisted of
2Gy TBI alone (n¼ 15), 2Gy TBI plus ﬂudarabine
90mg/m2 (n¼ 73), or 4Gy TBI plus ﬂudarabine 90mg/m2
(n¼ 18). TNFR1 levels increased signiﬁcantly from base-
line to day 7 after nonmyeloablative HCT (Po0.0001).
Patients conditioned with 4Gy TBI had higher TNFR1
day 7/baseline ratio than those conditioned with 2Gy TBI
(median 1.65 versus 1.25; P¼ 0.01). In a multivariate Cox
model, high TNFR1 day7/baseline ratio was associated
with grades II–IV (HR¼ 2.2, P¼ 0.01) and grades III–IV
(HR¼ 2.9, P¼ 0.007) acute GVHD, but had no impact
on overall survival (P¼ 0.8). In summary, our data
suggest that nonmyeloablative conditioning induces the
generation of TNF-a, and that the magnitude of TNF-a
generation depends on the conditioning intensity (2Gy
versus 4Gy TBI). Further, assessment of TNFR1 levels
before and on day 7 after nonmyeloablative HCT provided
useful information on subsequent risk of experiencing
acute GVHD.
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Introduction
Nonmyeloablative allogeneic hematopoietic cell transplan-
tation (HCT) has been increasingly used in patients with
hematological malignancies who are too old or too sick to
tolerate a myeloablative allogeneic HCT,1–4 as well as in
patients who had failed a high-dose transplant.5 This
approach relies on optimization of pre- and post transplant
immunosuppression to prevent host-versus-graft (rejection)
and excessive graft-versus-host reactions,6 and on graft-
versus-tumor effects mediated by donor T (and perhaps
NK) cells for tumor eradication.7,8
Myeloablative conditioning has been shown to contri-
bute to the physiopathology of GVHD, presumably by
inducing tissue damage and the release of a ‘cytokine
storm’ that activates donor T cells.9,10 TNF-a production
by activated donor T cells as well as activated macrophages
has been associated with acute GVHD both in mice and
in humans.11–13 Further, TNF receptor 1 (TNFR1) has
been used as a surrogate marker for TNF-a because its
concentration is closely correlated to that of TNF-a,14,15
and because it has superior stability to TNF-a in long-term
storage.16,17 Choi et al. and Kitko et al. recently reported
that TNFR1 plasma elevation from baseline to day 7 after
transplantation with myeloablative conditioning correlated
with GVHD severity and overall survival,16,17 whereas no
correlation was observed between GVHD and baseline or
day 7 TNFR1 levels.16,17
The biology of graft-versus-host reactions after non-
myeloablative conditioning differs from what occurs after
myeloablative conditioning in several aspects.18 First,
nonmyeloablative conditioning often leads to an initial
state of mixed donor–host chimerism that might favor
graft-versus-host tolerance and thus limit GVHD.19,20
Second, the intensity of the preparative regimens is by
deﬁnition greatly reduced in the setting of nonmyeloabla-
tive conditioning, potentially reducing or preventing the
‘cytokine storm,’21,22 and in particular the release of large
amounts of TNF-a by activated macrophages and donor
T cells. In addition, the number of recipient-derived APC
might be higher after nonmyeloablative than myeloablative
conditioning. As recipient-derived APC are thought to have
a major role in the initiation of acute GVHD,23 their
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enhanced persistence after a nonmyeloablative regimen
might favor acute GVHD. These observations prompted us
to investigate the role of TNF-a in the physiology of acute
GVHD after nonmyeloablative conditioning. Speciﬁcally,
we analyzed the impact of plasma TNFR1 elevation from
baseline to day 7 after HCT on acute GVHD and overall
survival in a cohort of 106 patients given PBSC from




Data from 106 patients transplanted from November 1999
to October 2008 at the University of Lie´ge were included in
the study. Results were analyzed as of February 2009.
Included in the analysis were patients with hematological
malignancies who were considered ineligible for conven-
tional allogeneic HCT because of age and/or co-morbidities,
or preceding extensive therapies such as a myeloablative
autologous or allogeneic HCT, as well as four patients with
metastatic renal cell carcinoma. Patient characteristics are
summarized in Table 1. Median patient age was 58 (range,
10–72) years. Twenty-seven patients had low-risk disease,
38 standard-risk disease, and 41 high-risk disease as deﬁned
by Kahl et al.24 Thirty-three patients received unmanipu-
lated PBSC from HLA-matched-related donors, 31 from
10/10 HLA allele-matched-unrelated donors, and 42 from
HLA-mismatched-related or -unrelated donor (1/10 HLA
allele mismatch (n¼ 13), 2/10 HLA allele mismatches
(n¼ 3), 1/10 HLA antigen mismatch (n¼ 16), 1/10 HLA
antigen plus 1/10 HLA allele mismatches (n¼ 7), 2/10 HLA
antigen mismatches (n¼ 3)). Written informed consent was
obtained from each patient to undergo nonmyeloablative
HCT and to collect, store, and analyze blood samples for
research purposes. The Ethics Committee of the University
of Liege approved the consent form as well as the current
research study protocol.
Treatment and evaluation. The nonmyeloablative condi-
tioning regimens consisted of 2Gy TBI alone (n¼ 15;
patients considered to be at low risk of graft rejection
because they had previously received chemotherapy and
were given PBSC from HLA-identical siblings), 2Gy TBI
with 90mg/m2 ﬂudarabine (n¼ 73, standard regimen), or
4Gy TBI with 90mg/m2 ﬂudarabine (n¼ 18, patients
considered to be at high risk of early disease progression
and/or graft rejection because of prior failed HCT (n¼ 9),
advanced B cell malignancy (n¼ 4), or myelodysplastic
syndrome (n¼ 5)). Post-grafting immunosuppression com-
bined mycophenolate mofetil with a calcineurin inhibitor
for all patients, as described earlier.25,26 Speciﬁcally, the
calcineurin inhibitor was given at full dose starting from
day 3, and until day 120 and then tapered off to stop by
day 180 in patients given grafts from HLA-identical
siblings, or until day 180 and then tapered off to stop by
day 365 in patients given grafts from alternative donors.
Mycophenolate mofetil was given from day 1 to day 28 in
patients given grafts from HLA-identical siblings, and from
day 1 to day 42 in those given grafts from alternative
donor. The duration of calcineurin inhibitor prophylaxis
was extended in patients with GVHD.
The diagnosis, clinical grading, and treatment of acute
GVHD were performed according to established criteria
for nonmyeloablative HCT.7,18 Speciﬁcally, patients with
signs/symptoms of acute GVHD without signs of chronic
GVHD beyond day 100 were classiﬁed as having acute
GVHD. Diagnosis and grading of chronic GVHD were
performed using the NIH consensus criteria.27 Treatment
was given for grades II–IV acute GVHD and for extensive
chronic GVHD, according to established guidelines.28
Table 1 Patient characteristics
Characteristic Value
Median patient age, years (range) 58 (10–72)
Median donor age, years (range) 41 (18–70)
Female donor to male recipient, # pts (%) 23 (22)
Diagnosis, # pts (%)
Acute myeloid leukemia 21 (20)
Myeloﬁbrosis 3 (3)
Chronic myeloid leukemia 3 (3)
Chronic lymphocytic leukemia 8 (7)
Myelodysplastic syndrome 15 (14)
Multiple myeloma 25 (24)
Non-Hodgkin lymphoma 23 (22)
Hodgkin disease 4 (4)
Renal cell carcinoma 4 (4)








Donor, # pts (%)
Related 36 (34)
HLA identical 33 (31)
1 HLA allele mismatch 1 (1)
1 HLA antigen mismatch 2 (2)
Unrelated 70 (66)
10/10 HLA allele match 31 (29)
1 HLA allele mismatch 12 (11)
41 HLA allele mismatch 27 (26)
Conditioning regimen, # pts (%)
2Gy TBI 15 (14)
2Gy TBI+ﬂudarabine 73 (69)
4Gy TBI+ﬂudarabine 18 (17)
Cell dose, median (range) ( 106/kg recipient)
CD34+ cells 4.6 (0.8–20.0)
T cells 334 (80–1215)






Day of onset of grades II–IV acute GVHD; median
(range)
38 (4–341)
3-year overall survival (%) 44
Abbreviation: HCT¼ hematopoietic cell transplantation.
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None of the patients received anti-TNF agents. Standard
prophylaxis against infections was used.26 Disease evalua-
tion was routinely carried out on days 40, 100, 180, 365 and
then at least yearly thereafter.
Samples and TNFR1 measurement
Blood samples were prospectively collected before the start
of the conditioning regimen, then on days 7, 14, 21, 28, 35,
42, 49, 56, 63, 70, 77, 84, 91, and 98 after HCT, and then
generally once every 2 weeks up to day 180. The serum
component of each blood sample was separated and frozen
for later analysis on the day of sample acquisition. TNFR1
serum concentration was retrospectively assessed using a
cytokine enzyme-linked immunoabsorbent assay (R&D,
Minneapolis, MN, USA) according to the manufacturer’s
protocol. All samples and standards were run in duplicate.
Chimerism analysis
Chimerism among total peripheral blood T cells was
assessed on days 28, 40, 100, 180, and 365 after HCT using
ﬂuorescence in situ hybridization to detect X and Y
chromosomes for recipients of sex-mismatched transplants
and PCR-based analysis of polymorphic microsatellite
regions for recipients of sex-matched transplants.25,26,29,30
CD3 (T cells) selection was carried out with RosetteSep
(StemCell Technologies, Vancouver, BC, Canada) as des-
cribed earlier.26
Statistical analyses
TNFR1 levels before and on day 7 after HCT were
compared with the Wilcoxon-matched pair test. Their
association was analyzed with the Spearman test. TNFR1
levels in patients with or without acute GVHD were
compared with the Mann–Whitney test. Potential pre-
transplant factors affecting donor T-cell chimerism levels
(TNFR1 day7/baseline ratio, number of T cells trans-
planted, number of CD34þ cells transplanted, ﬂudarabine
use or not, 2 or 4Gy TBI, HLA mismatching or not, donor
type, patient age) and TNFR1 day7/baseline ratio (number
of T cells transplanted, number of CD34þ cells trans-
planted, ﬂudarabine use or not, 2 or 4Gy TBI, HLA
mismatching or not, donor type, patient age, disease risk)
were determined using multivariate linear regression
models. Survival was estimated using the Kaplan–Meier
method. Comparison between survival curves was carried
out with the log rank test. Multivariate Cox models were
performed for acute GVHD, progression/relapse, and
overall survival (HR and 95% conﬁdence intervals). For
acute GVHD, factors introduced in the models included
TNFR1 day7/baseline ratio, 2 or 4Gy TBI, HLA
mismatching or not, donor type, donor or recipient CMV
seropositivity, patient age, and female donor to male
recipient or other gender combination. For relapse/
progression and overall survival, factors introduced in the
models included TNFR1 day7/baseline ratio, HLA mis-
matching or not, donor type, donor or recipient CMV
seropositivity, patient age, disease risk, comorbidity
at HCT, and female donor to male recipient versus
other gender combinations. Statistical analyses were done
with Graphpad Prism (Graphpad Software, San Diego,
CA, USA) or with SAS version 9.1 (SAS Institute, Cary,
NC, USA).
Results
Factors affecting TNFR1 day 7/baseline ratio
There was a close correlation between baseline (pre-condition-
ing) and day 7 TNFR1 levels (Spearman R¼ 0.7, Po0.0001).
However, TNFR1 levels increased signiﬁcantly from base-
line (2753±1886pg/ml) to day 7 (3781±2,803pg/ml) after
nonmyeloablative HCT (Po0.0001). Median TNFR1 day 7/
baseline ratio was 1.3 (range, 0.8–3.9), with four patients
having a TNFR1 day 7/baseline ratio X2.5. In univariate
analysis, patients conditioned with 4Gy TBI had higher
TNFR1 day 7/baseline ratios than those conditioned with
2Gy TBI (1.65 versus 1.25; P¼ 0.01) (Figure 1). In a
multivariate model, the association between TBI dose and
TNFR1 day 7/baseline ratios (modeled as a linear continuous
variable) remained statistically signiﬁcant (P¼ 0.017), whereas
number of T cells (P¼ 0.7) or CD34þ cells (P¼ 0.7)
transplanted, disease risk (P¼ 0.4), donor type (P¼ 0.5),
HLA matching (P¼ 0.5), ﬂudarabine use (P¼ 0.7), and
patient age (P¼ 0.2) had no statistically signiﬁcant impact
on TNFR1 day 7/baseline ratios.
Factors affecting day 28T-cell chimerism levels
In multivariate analysis, patients given 4Gy TBI had higher
day 28 T-cell chimerism levels than those given 2Gy TBI
(P¼ 0.02), whereas those given grafts from HLA-identical
siblings had lower T-cell chimerism than those given grafts
from HLA-matched-unrelated (P¼ 0.01) or HLA-mis-
matched donors (P¼ 0.01). In contrast, there were no
associations between day 28 donor T-cell chimerism levels
and TNFR1 day 7/baseline ratio (modeled as a linear
continuous variable, P¼ 0.8), number of transplanted
T cells (P¼ 0.6), number of transplanted CD34þ cells
(P¼ 0.4), patient age (P¼ 0.1), and ﬂudarabine use or not
(P¼ 0.7).
Day 28 donor T-cell chimerism levels were higher in
patients with grades II–IV acute GVHD, than in patients
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Figure 1 TNFR1 day 7/baseline ratio in patients conditioned with 2
or 4Gy TBI (P¼ 0.01).
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excluding data from patients who had acute GVHD before
day 28 after HCT, there was a suggestion that increasing
day 28 donor T-cell chimerism levels were associated with a
higher risk of subsequent grades II–IV acute GVHD: 8% of
patients with day 28 donor T-cell chimerism levels p50,
versus 38% of those with levels 450% developed grades
II–IV acute GVHD (P¼ 0.053).
Association between TNFR1 day 7/baseline ratio
and acute GVHD
Acute GVHD of grades II, III, and IV was observed in 28,
8, and 9 patients, respectively. Median time for diagnosis of
grades II–IV acute GVHD was 38 (range, 4–341) days, with
only one patient experiencing acute GVHD before day 7.
Eight of 18 patients (44%) given 4Gy TBI in their
conditioning regimen experienced grades II–IV acute
GVHD, whereas 37 of 88 patients (42%) conditioned with
2Gy TBI did so. Factors associated with acute GVHD in
univariate and multivariate analyses are listed in Tables 2
and 3. In a multivariate Cox model, high TNFR1
day 7/baseline ratio (modeled as a continuous linear
variable) was the only factor statistically signiﬁcantly
associated with a higher risk of grades II–IV (HR 2.2,
P¼ 0.01) (Figure 2a) and grades III–IV (HR 2.9, P¼ 0.007)
acute GVHD (Tables 2 and 3). There was also a trend for
an association between a high incidence of grades II–IV
acute GVHD and HLA disparity between donor and
recipient, older patient age, and female donor to male
recipient (Tables 2 and 3), although these factors did not
reach statistical signiﬁcance perhaps because of the
relatively small number of patients analyzed. Interestingly,
day 7 TNFR1 levels were not statistically signiﬁcantly
associated with grades II–IV acute GVHD (P¼ 0.07),
suggesting that TNFR1 day 7/baseline ratio predicts better
for acute GVHD than TNFR1 day 7 alone (as also
observed by other groups of investigators16,17).
Impact of acute GVHD occurrence on TNFR1 levels
As shown in Figure 2a, compared to those without grades
II–IV acute GVHD, patients developing grades II–IV acute
GVHD had higher relative TNFR1 levels on day 7 (NS)
and on day 35 (P¼ 0.04), but not on day 63 after HCT. To
further analyze the role of TNF in acute GVHD after
nonmyeloablative conditioning, we compared TNFR1
levels at onset of acute GVHD (median, day 38) in patients
with grades II–IV acute GVHD, versus TNFR1 levels
around day 35 after HCT in patients who never experienced
grades II–IV acute GVHD. Patients developing grades II–
IV acute GVHD had higher absolute (5957±3498 pg/ml
versus 4555±3733 pg/ml, P¼ 0.0146), and relative (deﬁned
as TNFR1 at the time of GVHD (or day 35) divided by
baseline TNFR1 level; 2.5±1.5 versus 1.8±1.0, P¼
0.0089) TNFR1 levels at onset of GVHD than those with-
out acute GVHD around day 35 after HCT (Figure 2b).
Association between TNFR1 day 7/baseline ratio
and relapse/progression
One- and 3-year incidences of relapse/progression were 40
and 47%, respectively. In multivariate analysis, high
disease risk was associated with a high risk of relapse/
progression (HR 2.1, P¼ 0.001), whereas TNFR1 day 7/
baseline ratio (modeled as a continuous linear variable) was
not (HR 0.6, P¼ 0.2) (Table 4).
Association between TNFR1 day 7/baseline ratio
and overall survival
One- and 3-year overall survival rates were 65 and 45%,
respectively. In multivariate analysis, unrelated donor
(P¼ 0.01), high disease risk (P¼ 0.05), and higher patient
age (P¼ 0.03) were each associated with a higher risk of
mortality, whereas TNFR1 day 7/baseline ratio (modeled
as a continuous linear variable) was not (P¼ 0.8) (Table 4).
Speciﬁcally, 3-year survival was 46% in patients with
TNFR1 day 7/baseline ratio p1.3, versus 44% in those
with TNFR1 day 7/baseline ratio 41.3 (Figure 3).
Discussion
After myeloablative conditioning, several observations
have suggested that high-dose chemo-radiotherapy induced
TNF-a production/secretion by macrophages in response
to TLR ligands and by activated T cells.9,10,31 Although
other cytokines have also been involved in the physio-
pathology of acute GVHD, the role of TNF-a as a critical
mediator of acute GVHD has been well established in
murine models.11,32 Further, persistent elevation of TNF-a
levels has been observed before and at onset of acute
GVHD in human HCT recipients.12 The biology of graft-
versus-host reactions after nonmyeloablative conditioning
Table 2 Factors predicting acute GVHD in univariate analysis
Factor Grades II–IV acute GVHD Grades III–IV acute GVHD
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
TNFR1 day 7/baseline ratioa 2.1 (1.2–3.8) 0.01 3.7 (1.8–7.4) 0.0002
Dose of total body irradiation (4Gy versus 2Gy) 1.1 (0.7–1.6) 0.7 1.6 (0.9–2.7) 0.08
HLA-identical alternative versus HLA-identical sibling donor 1.6 (0.6–3.9) 0.3 1.5 (0.3–7.2) 0.6
HLA mismatched versus HLA-identical sibling donor 1.2 (0.6–2.4) 0.5 1.6 (0.6–4.6) 0.3
Donor or recipient CMV seropositivity 0.7 (0.4–1.4) 0.3 0.4 (0.2–1.1) 0.07
Patient agea 1.02 (0.99–1.05) 0.2 1.03 (0.97–1.08) 0.3
Female donor to male recipient versus other gender combinations 1.4 (0.7–2.7) 0.3 0.4 (0.1–1.8) 0.3
Abbreviation: TNFR1¼TNF receptor 1.
Bold values indicate P-value o0.05.
aModeled as a linear continuous variable.
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differs from what occurs after myeloablative conditioning
in several aspects.18 In particular, the intensity of the
preparative regimens and transplant-related toxicities are
by deﬁnition greatly reduced in the setting of nonmyelo-
ablative conditioning.33 This prompted us to investigate the
role of TNF-a in the biology of acute GVHD after
nonmyeloablative conditioning. We used TNFR1 as a
surrogate marker for TNF-a, given that it is more stable in
long-term storage and that previous work had shown that
TNFR1 was elevated in patients with GVHD, and
correlated with TNF-a levels.16,17 Several observations
were made.
First, TNFR1 levels were signiﬁcantly higher on day 7
after nonmyeloablative HCT than before transplantation.
However, median TNFR1 day 7/baseline ratio seemed to
be lower after nonmyeloablative conditioning than has
been observed by other groups of investigators in patients
given allogeneic grafts after myeloablative conditioning.16
Indeed, only 4 of 106 patients given nonmyeloablative
conditioning in this study had a TNFR1 day 7/baseline
ratio X2.5, whereas 25% of patients given myeloablative
conditioning had such a ratio in the Choi study.16 The
impact of conditioning intensity on TNFR1 increases after
HCT was also directly shown in this study, as patients given
4Gy TBI had higher TNFR1 day 7/baseline ratio than
those given 2Gy TBI (P¼ 0.01). Nevertheless, our data
also suggest that donor/recipient alloreactivity might also
inﬂuence TNFR1 levels after nonmyeloablative condition-
ing as TNFR1 levels continue to increase from day 7 to day
35 after HCT (Figure 2b).
The most important observation of our study was the
association between high TNFR1 day 7/baseline ratio and
the probability of developing grades II–IV and grades III–
IV acute GVHD. This is in agreement with previous papers
analyzing data from patients given myeloablative condi-
tioning.16,17 We could not use the TNFR1 ratio X2.5 as a
cutpoint for predicting patients at risk for acute GVHD (as
done by other groups of investigators16,17) because only
four patients in our study had such a ratio. However,
interestingly, these four patients all experienced grades II–
IV acute GVHD. If conﬁrmed in further prospective
studies, the current observation could lead to the develop-
ment of protocols aimed at preventing severe acute GVHD
in patients with high TNFR1 increment on day 7 after
nonmyeloablative HCT by maximizing post-grafting im-
munosuppression or administrating anti-TNF agents.
Another important observation in this study was the
elevated TNFR1 levels in patients at onset of grades II–IV
acute GVHD compared with patients without acute
GVHD. This is in full agreement with a prior paper
assessing TNFR1 levels in patients with acute GVHD after
myeloablative conditioning.13
The TNFR1 day 7/baseline ratio had no impact on
overall survival in this paper. This is in contrast to what has
been observed in patients given myeloablative condition-
Table 3 Factors predicting acute GVHD in a multivariate Cox model
Factor Grades II–IV acute GVHD Grades III–IV acute GVHD
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
TNFR1 day 7/baseline ratioa 2.2 (1.2–4.2) 0.01 2.9 (1.3–6.2) 0.007
Dose of total body irradiation (4Gy versus 2Gy) 1.0 (0.6–1.5) 0.9 1.3 (0.7–2.3) 0.4
HLA-identical alternative versus HLA-identical sibling donor 1.7 (0.7–4.4) 0.3 1.4 (0.3–7.2) 0.7
HLA mismatched versus HLA-identical sibling donor 1.4 (0.7–2.7) 0.4 1.7 (0.6–5.0) 0.3
Donor or recipient CMV seropositivity 0.7 (0.4–1.4) 0.4 0.4 (0.1–1.1) 0.07
Patient agea 1.02 (0.99–1.05) 0.3 1.01 (0.96–1.07) 0.6
Female donor to male recipient versus other gender combinations 2.0 (1.0–4.2) 0.066 0.8 (0.2–3.9) 0.8
Abbreviation: TNFR1¼TNF receptor 1.
Bold values indicate P-value o0.05.
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Figure 2 (a) Evolution of relative (deﬁned as TNFR1 levels at the
observed day divided by baseline TNFR1 levels) TNFR1 levels on days 7,
35, and 63 after HCT in patients with or without grades II–IV acute
GVHD. (b) TNFR1 levels (mean±standard deviation) on the day of onset
(median 38 days after HCT) of GVHD in patients with grades II–IV acute
GVHD, or around day 35 after HCT in patients without GVHD
(P¼ 0.01).
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ing.16,17 This could be due to the fact that only 6 of our 106
patients died from acute GVHD. Interestingly, we did not
observe a signiﬁcant association between TNFR1 day 7/
baseline ratio and the risk of relapse/progression. This is in
agreement with previous observations showing that acute
GVHD is not associated with graft-versus-tumor effects
after nonmyeloablative conditioning.7,34
In summary, our data suggest that nonmyeloablative
conditioning induces the generation of TNF-a, and that the
magnitude of TNF-a generation depends on the condition-
ing intensity (2Gy versus 4Gy TBI). Further, assessment of
TNFR1 levels before and on day 7 after nonmyeloablative
HCT provides useful information on subsequent risk of
experiencing acute GVHD.
Conﬂict of interest
The authors declare no conﬂict of interest.
Acknowledgements
We are grateful to physicians, physicians’ assistants, and clinical
staff for their dedicated care of the patients. FB is a senior
research associate and YB a research director of the National
Fund for Scientiﬁc Research (F.R.S.-FNRS) Belgium. The study
was in part supported by funds from the FNRS, the Anti-Cancer
Center from the University of Lie´ge, and by the Belgian
Federation against Cancer (FBC).
References
1 McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM,
Molina AJ, Maloney DG et al. Hematopoietic cell transplant-
ation in older patients with hematologic malignancies: repla-
cing high-dose cytotoxic therapy with graft-versus-tumor
effects. Blood 2001; 97: 3390–3400.
2 Sandmaier BM, Mackinnon S, Childs RW. Reduced intensity
conditioning for allogeneic hematopoietic cell transplantation:
current perspectives. Biol Blood Marrow Transplant 2007; 13:
87–97.
3 Baron F, Sandmaier BM, Storer BE, Maris MB, Langston
AA, Lange T et al. Extended mycophenolate mofetil and
shortened cyclosporine failed to reduce graft-versus-host
disease after unrelated hematopoietic cell transplantation with
nonmyeloablative conditioning. Biol Blood Marrow Transplant
2007; 13: 1041–1048.
4 Maris MB, Sandmaier BM, Storer BE, Maloney DG, Shizuru
JA, Agura E et al. Unrelated donor granulocyte colony-
stimulating factor-mobilized peripheral blood mononuclear
cell transplantation after nonmyeloablative conditioning: the
effect of postgrafting mycophenolate mofetil dosing. Biol
Blood Marrow Transplant 2006; 12: 454–465.
5 Baron F, Storb R, Storer BE, Maris MB, Niederwieser D,
Shizuru JA et al. Factors associated with outcomes in
allogeneic hematopoietic cell transplantation with nonmyelo-
ablative conditioning after failed myeloablative hematopoietic
cell transplantation. J Clin Oncol 2006; 24: 4150–4157.
6 Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem H-P
et al. Stable mixed hematopoietic chimerism in DLA-identical
littermate dogs given sublethal total body irradiation before
and pharmacological immunosuppression after marrow trans-
plantation. Blood 1997; 89: 3048–3054.
7 Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M,
Diaconescu R et al. Graft-versus-tumor effects after allogeneic
hematopoietic cell transplantation with nonmyeloablative
conditioning. J Clin Oncol 2005; 23: 1993–2003.
8 Baron F, Petersdorf EW, Gooley T, Sandmaier BM, Malkki M,
Chauncey TR et al.What is the role for donor natural killer cells
after nonmyeloablative conditioning? Biol Blood Marrow
Transplant 2009; 15: 580–588.
Table 4 Factors predicting mortality in a multivariate Cox model
Factor Relapse/progression Mortality
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
TNFR1 day 7/baseline ratioa 0.6 (0.3–1.3) 0.2 1.1 (0.6–1.8) 0.8
HLA-identical nonfamilial versus HLA-identical sibling donor 0.7 (0.2–2.1) 0.5 2.9 (1.3–6.6) 0.01
HLA mismatched versus HLA-identical sibling donor 0.7 (0.3–1.5) 0.3 1.4 (0.7–2.8) 0.4
Disease risk 2.1 (1.3–3.3) 0.001 1.5 (1.0–2.2) 0.049
Donor or recipient CMV seropositivity 2.5 (0.9–6.4) 0.07 1.5 (0.7–3.2) 0.35
Comorbidity (HCT-CI scorea) 1.0 (0.8–1.2) 0.8 1.1 (0.9–1.3) 0.3
Patient agea 1.02 (0.99–1.05) 0.2 1.04 (1.00–1.08) 0.028
Female donor to male recipient versus other gender combinations 0.5 (0.2–1.3) 0.16 1.3 (0.6–2.6) 0.5
Abbreviations: HCT¼ hematopoietic cell transplantation; TNFR1¼TNF receptor 1.
Bold values indicate P-value o0.05.
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Figure 3 Overall survival in patients with a TNFR1 day 7/baseline ratio
below or above 1.3 (median) (P¼ 0.88).
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